ALP is an enzyme found primarily in the liver, bile ducts, and bones. It's most useful for detecting bile duct problems or bone turnover issues, rather than general liver cell damage.
Elevated ALP is interpreted based on which tissue it's coming from. When accompanied by elevated GGT, bile duct involvement is likely, whether from obstruction, cholestasis, or drug effects. When GGT is normal but ALP is high, bone origin is more probable, as with Paget's disease, bone turnover, or growing children (in whom elevated ALP is normal). Low ALP can indicate zinc deficiency, malnutrition, or hypophosphatasia. ALP interpretation benefits from knowing both liver and bone context.
Optimal Alkaline Phosphatase: 70-100 U/L.
Typically re-tested every 12 weeks.
ALP appears on most standard blood chemistry panels, usually reported as a single total number rather than split by tissue of origin. That makes it a screening signal, better at raising a question than answering one. The question it raises is almost always the same, is this enzyme coming from bone, from the liver, or from something temporary.
Alkaline phosphatase is a family of enzymes that remove phosphate groups from molecules and work best in an alkaline environment, measured in blood as one combined total.
The enzyme exists in several isoforms. The tissue-nonspecific form is produced in bone, liver and kidney, while separate forms come from the intestine and, during pregnancy, the placenta 1. In a healthy non-pregnant adult, most of the ALP circulating in blood comes from just two places, the osteoblasts that build bone and the cells lining the bile canaliculi in the liver. A standard panel measures all of these at once, which is why the number on its own cannot say where it came from.
In bone, the tissue-nonspecific form sits on the surface of osteoblasts and breaks down inorganic pyrophosphate, a molecule that otherwise blocks mineral from depositing into the bone matrix. Clearing that brake is what allows calcium and phosphate to crystallise into new bone, and the clinical importance of that step is shown by hypophosphatasia, an inherited condition in which reduced activity of this enzyme impairs mineralisation 2. So when bone is actively being remodelled, whether by normal growth, fracture healing or accelerated turnover, more of this enzyme spills into the blood.
In the liver, ALP is anchored to the membrane facing the tiny channels that carry bile. When bile flow is slowed or obstructed anywhere from the liver cell to the main bile duct, production of the enzyme increases and more of it is released into circulation. This is why ALP is grouped with the cholestatic liver markers rather than the markers of liver cell injury.
It matters because it tracks two systems that quietly age, the biliary side of the liver and the ongoing remodelling of bone and blood vessels.
On the liver side, ALP is more than a one-off flag. In primary biliary cholangitis, an international follow-up study found that ALP and bilirubin levels function as surrogate end points for long-term outcomes, meaning the level tracked over time carried prognostic information about the course of the condition 3. That is a specific population, not the general public, but it illustrates why clinicians watch the trend rather than a single reading.
On the bone and vascular side, the same enzyme that mineralises bone is also studied in the mineralisation of arteries. In people receiving maintenance hemodialysis, research suggests serum ALP is associated with cardiac valve calcification 4, and circulating bone-specific ALP has been linked with abdominal aortic calcification in the same setting 5. Studies indicate associations with harder outcomes too, including in-hospital mortality among people admitted with acute ischemic stroke 6 and infection-related mortality over ten years of follow-up in a dialysis cohort 7.
Those findings come from populations with significant existing disease, so they should not be read as a forecast for a healthy adult with a mildly raised number. They do explain why an ALP result that drifts upward over repeat panels is worth a conversation rather than a shrug.
There is also a metabolic thread. In a study of adults, serum ALP was associated with the triglyceride to HDL ratio and the triglyceride glucose index, two indirect markers of insulin resistance 8. Association is not causation here, and the practical takeaway is narrow, ALP is one of several routine chemistry values that tend to move with overall metabolic health rather than sitting in isolation.
Most adult labs report a wide reference interval, and FitScript applies a narrower optimisation target inside it.
| Measure | Range (U/L) | What it represents |
|---|---|---|
| Standard lab reference range, adults | 44 to 147 | The typical adult reference interval reported by many laboratories |
| FitScript optimal range, adults | 70 to 100 | FitScript's optimisation target for adults |
Reference ranges vary by laboratory, assay method, age and sex, so always read your result against the interval printed on your own report. FitScript's optimal range is an optimisation target, not a diagnostic cut-off, and a result outside it is not a finding on its own.
Two groups predictably sit above the adult interval for reasons that have nothing to do with illness. Children and adolescents run higher because growing bone is constantly mineralising, with the highest values around growth spurts. Pregnancy raises total ALP as well, because the placenta produces its own isoform; a study of a large sample of pregnant women described how total ALP levels differ by gestational age, rising as pregnancy advances 9. A result that looks high against an adult reference interval may be entirely expected in those contexts, which is one more reason interpretation belongs with a clinician who knows the full picture.
A result above the reference interval usually means more enzyme is entering the blood from bone, from the biliary system, or from a temporary physiological source, and the next step is working out which.
Symptoms people report. Often none at all, which is why raised ALP is frequently picked up on a routine panel. When the biliary system is involved, people may describe itching, unusually pale stools, darker urine, yellowing of the eyes or skin, fatigue, or discomfort under the right ribs. When bone turnover is the source, people more often report bone or joint aching, or nothing noticeable. Symptoms are not a reliable way to tell the two apart.
Common causes. Physiological causes come first, including adolescent growth, the later stages of pregnancy and the weeks after a fracture while bone is healing. Biliary causes include anything that slows bile flow, from gallstones to bile duct narrowing to cholestasis from medication. Bone causes include accelerated remodelling, which can accompany low vitamin D status, overactive parathyroid function, Paget disease of bone, or healing after orthopaedic surgery. Intestinal and, rarely, tumour-related sources also exist, and in osteosarcoma a meta-analysis reported that higher ALP is associated with poorer prognosis 10. At the other end of life, serial ALP has been studied as an early biomarker for osteopenia of prematurity in preterm infants 11, another reminder that the enzyme is a bone signal as much as a liver one.
Long-term impact and the next step. A mildly raised result that returns to range on a repeat test is common and often reflects something temporary. A result that stays elevated across repeat panels is the one worth attention. The practical sequence is observation, then inference, then a conversation. The observation is the number and its trend. The inference is which compartment is likely responsible, which is usually clarified by looking at bile duct and liver cell markers alongside it, plus calcium, phosphate and vitamin D status. The conversation belongs with a clinician, and a markedly elevated result, or one accompanied by jaundice, pale stools or persistent right-sided abdominal pain, is worth discussing with a clinician promptly rather than at the next routine visit.
A result below the reference interval is less common, usually reflects reduced enzyme production or missing cofactors, and is interpreted alongside nutrition, thyroid status and bone health.
Symptoms people report. Most people with a slightly low value notice nothing. In the inherited condition hypophosphatasia, where enzyme activity is genuinely reduced, the picture can include early loss of primary teeth, bone pain, poor mineralisation and fractures that heal slowly, and the severity varies widely between individuals 2.
Common causes. Zinc and magnesium act as cofactors for the enzyme, so low status of either is a recognised contributor to a low reading. Other associations include underactive thyroid function, low protein intake or general undernutrition, malabsorption, severe anaemia and, in some cases, medications or supplements taken in large amounts over time. Because the assay measures enzyme activity, anything that limits the enzyme's function can pull the number down without a disease being present.
Long-term impact and the next step. The concern with a persistently low result is bone mineralisation, since the enzyme's role is to clear the brake on mineral deposition. A single low value means little on its own. A repeatedly low value, particularly alongside dental problems, unexplained fractures or bone pain, is worth raising with a clinician who can decide whether further assessment of mineral metabolism makes sense. Low results should be investigated, not dismissed as the harmless opposite of a high one.
Several ordinary factors move ALP without any underlying problem, which is why a single out-of-range value is usually repeated before anything is concluded.
Testing conditions. The intestinal isoform can rise modestly after a fatty meal in some people, so fasting samples are more comparable from one draw to the next. Time of day, recent intense exercise and sample handling can all introduce small differences, as can a change of laboratory or assay, since methods and reference intervals are not identical between labs.
Life stage and physiology. Growth, pregnancy and recent fracture healing all raise the number for reasons that are entirely expected 9. Age and sex shift the typical interval too, which is why your lab's own range matters more than a generic one.
Medications and supplements. Some medicines influence ALP through the liver, others through bone. Research in humans found that rifampicin induces the bone form of alkaline phosphatase, raising the measured total without a liver problem being present 12. Never stop or change a prescribed medication because of a lab value; bring the result to the prescribing clinician instead.
Habits and nutrition. Alcohol intake, overall diet quality, zinc and magnesium status and vitamin D status all sit in the background of this marker. Those levers are covered in depth elsewhere; the short version here is that a drifting ALP is usually a prompt to look at the liver, the bones and nutrient status together, not a problem to be solved in isolation.
Alkaline phosphatase is a standard component of comprehensive blood chemistry and liver panels, and it is included in FitScript's biomarker testing, which covers 150+ biomarkers tested per year across repeat draws.
Testing repeatedly is what makes this marker useful. A single value answers very little, because the reference interval is wide and the enzyme has more than one source. A series of values taken under similar conditions shows direction, and direction is what clinicians act on. Atlas, FitScript's AI health advisor, reads the result in context with the liver and bone markers drawn at the same time and turns that into your FitScript, the personalised output written from your own biology rather than from population averages.
What testing can show is a pattern, whether ALP is stable, rising or falling, and whether the markers around it point toward bile flow, bone turnover or neither. What it cannot show is a diagnosis. Imaging, history, examination and sometimes isoenzyme fractionation are what separate the possible explanations, and those decisions sit with a licensed provider. If a prescription therapy ever becomes part of the conversation, a licensed provider evaluates whether it is appropriate after reviewing the full clinical picture.
ALP becomes interpretable the moment it is read next to the markers that identify its source. The usual companions separate the biliary system from liver cell injury, then check the bone and mineral side.
The single most useful partner is GGT, which rises with biliary causes but not with bone causes, making it the standard way to work out where the enzyme is coming from; ALT and AST indicate liver cell injury rather than obstructed bile flow, so a raised ALP with quiet transaminases points in a different direction than one with all three elevated; Bilirubin Total adds the functional question of whether bile is actually clearing; Calcium and Vitamin D (25-OH) cover the mineral metabolism side, since bone turnover driven by low vitamin D status or parathyroid overactivity is a common explanation for a bone-pattern result; and because ALP has been associated with insulin resistance indices 8, the Metabolic + Insulin panel adds the metabolic context that a liver and bone panel alone leaves out.
Alkaline phosphatase is an enzyme from bone and bile ducts measured as one total number. Typical adult labs report roughly 44 to 147 U/L, and FitScript's optimal range is 70 to 100 U/L as an optimisation target rather than a cut-off. High results point toward bone turnover, slowed bile flow or a normal life stage such as growth or pregnancy. Low results point toward cofactor and nutrition status or, rarely, a genetic cause. The trend across repeat tests is more informative than any single draw.
This page is educational and is not medical advice. Discuss your own results, and any treatment decision, with a clinician or licensed provider who can see your full history.
It measures the combined activity of several related enzymes in your blood, most of which come from bone-building cells and from the lining of the liver's bile ducts. The intestine contributes a small amount, and during pregnancy the placenta adds its own form. Because the result is a single total, it shows that enzyme activity has changed but not which tissue it came from.
Many laboratories report a typical adult reference interval of about 44 to 147 U/L. FitScript's optimal range for adults is 70 to 100 U/L, which is an optimisation target rather than a diagnostic cut-off. Reference intervals differ by laboratory, assay, age and sex, so compare your value with the range printed on your own report.
That pattern often points toward bone rather than the liver. Growth in adolescence, healing after a fracture, accelerated bone remodelling and low vitamin D status can all raise the bone form of the enzyme while liver markers stay quiet. GGT is the usual tie-breaker, since it rises with bile flow problems but not with bone turnover. A clinician can confirm which explanation fits.
No. Several entirely expected situations raise it, including adolescent growth, the later stages of pregnancy and recovery from a fracture. A single mildly elevated value is often repeated before anything is concluded. What deserves more attention is an elevation that persists across repeat panels, or one accompanied by jaundice, pale stools, dark urine or persistent right-sided abdominal pain, which is worth discussing with a clinician promptly.
Low readings are less common and often relate to the cofactors the enzyme needs, particularly zinc and magnesium. Underactive thyroid function, low protein intake, malabsorption and severe anaemia are other recognised associations. Rarely, a persistently low value reflects hypophosphatasia, an inherited condition affecting bone mineralisation. A repeatedly low result alongside dental problems or unexplained fractures is worth raising with a clinician.
Fasting is preferred for comparability. The intestinal form of the enzyme can rise modestly after a fatty meal in some people, which adds noise when you are tracking a trend over time. Drawing samples under similar conditions, ideally at the same laboratory, makes successive results far easier to compare.
Yes. Some medicines act through bone and raise the bone form of the enzyme, lifting the measured total without a liver problem being present. Never stop or adjust a prescribed medication because of a lab value; bring the result to the prescribing clinician instead.
GGT first, because it separates biliary causes from bone causes. ALT, AST and total bilirubin add the liver cell injury and bile clearance picture, while calcium and vitamin D cover the mineral and bone side. Metabolic markers add useful context, since this enzyme is associated with indices of insulin resistance.
Retesting frequency depends on why it was checked and what the result showed, so the interval is a clinical decision rather than a fixed rule. In general, the trend across repeat draws carries more information than any single value, which is why FitScript's membership is built around repeat biomarker testing rather than a one-off snapshot.